In connection to the above, experimental studies will be needed to foster our understanding of the regulation of RUNX1 in the heterogeneous cellular contexts of MDS and ultimately deliver patient‐tailored therapeutic avenues. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.